Ten23 announces Swiss manufacturing expansion  

Global contract development and manufacturing organisation (CDMO) ten23 health has announced an expansion to its facility in Switzerland. 

The company is expanding swissfillon’s manufacturing site, a sterile filling supplier who joined ten23 in 2021.  

Ten23 will expand the site with a new manufacturing building which will constitute 5,000 square metres of space over four floors. The building will accommodate three additional manufacturing lines alongside technical areas, offices and laboratories. The superstructure of the building is expected to be completed in summer 2022, with the full plant aiming to be fully operational in 2024. 

In this new facility ten23 health plans to build two further sterile manufacturing lines and provide GMP fill & finish capacity for commercial as well as clinical use. The company states that when fully operational, the new building and production lines could create over 100 jobs for the region.  

Official comments  

Professor Dr Hanns-Christian Mahler, CEO of ten23 health, commented: “The significant expansion of our production capacity for syringe and capsule filling, and technical capabilities of filling and lyophilization of sterile products in bulk vials is a clear commitment for Switzerland, and will enable our customers to provide treatment options for their patients.” 

 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free